HEALTH OF WOMAN. 2015.8(104):106–109 

Progesterone and the risk of late complications of pregnancy 

Nazarenko L., Nikifor L.

Kharkiv medical Academy of postgraduate education

Bukovinian state medical University, Chernivtsi 

The purpose of research – assessment of the effectiveness of progesterone support in women with late complications of pregnancy, with signs of fetoplacental dysfunction. The study involved 65 women with clinically outlined fetoplacental pathology – IUGR I-II (15), oligogidgamnion (20), a combination (25), hypoplasia of the placenta (5), starting with the 24–27 week period. Before treatment, pharmacological tests were carried out to assess the potential benefits of progesterone support by investigating the effect of sublingual form of progesterone in the blood flow in the structures of utero-placental-fetal vascular bed. The positive effect of the use of progesterone in the incidence of preterm labor women with late pregnancy complications associated with fetoplacental dysfunction. Progesterone significant effect when used in the 2nd half of pregnancy on perinatal mortality, neonatal morbidity not established. It is concluded that the prospects for further research on large clinical material, in a randomized format. 

Key words: progesterone, pregnancy complications, premature birth. 

REFERENCES

1. Айламазян ЭК, Баранов ВС. 2002. Молекулярная медицина – новое направление в акушерстве и гинекологии. Акушерство и гинекология 4:9–14.

2. Моісеєнко РО, Терещенко АВ. 2013. Аналітичні матеріали щодо стану охорони здоров’я матерів та дітей в Україні у 2007–2011 роках. Неонатологія, хірургія та перинатальна медицина 1(7):6–12.

3. Невынашивание беременности: патогенез, диагностика, лечение (клиническое руководство): под ред. АН Стрижакова и соавт.- ГОУ ВПО 1 Моск. гос. мед. ин-т. 2011:71.

4. Сидельникова ВМ, Сухих ГТ. 2010. Невынашивание беременности: Руководство для практикуючих врачей. М, ООО «Медицинское информационное агентство»:536.

5. Bohm F. 2005. The endotelin-1 receptor antagonist bosentan protects against ischemia/ reperfusion-induced endothelial dysfunctions in humans. Clin. Sci. 108;4:357–363. http://dx.doi.org/10.1042/CS20040317; PMid:15610070

6. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. 2003. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous PTB in women at increased risk: a randomized placebo-controlled double-blind study. Am. J. Obstet. Gynecol. 188:419–424. http://dx.doi.org/10.1067/mob.2003.41; PMid:12592250

7. Fonseca EB, Celik E, Parra M et al. 2007. Progesterone and the risk of preterm birth among women with a short cervix. Engl. J. Med. 357:462–469. http://dx.doi.org/10.1056/NEJMoa067815; PMid:17671254

8. DeFranco EA, O’Brien JM, Adair CD et al. 2007. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet. Gynecol. 30:697–705. http://dx.doi.org/10.1002/uog.5159; PMid:17899571

9. Graham JD, Clarke CL. 1997. Physiological action of progesterone in target tissue. Endocrine Reviews 18;4:502–519. http://dx.doi.org/10.1210/er.18.4.502; http://dx.doi.org/10.1210/edrv.18.4.0308; PMid:9267762

10. Menon R. 2012. Preterm birth: a global burden on maternal and child health. Pathog. Glob. Health 106(3):139–140. http://dx.doi.org/10.1179/204777312X13462106637729; PMid:23265368 PMCid:PMC4001570